Here in the United States Cannabidiol (CBD) is legal in all 50 states if the Tetrahydrocannabinol (THC) concentration of the product is no more than 0.3%. The largest retailers of CBD in 2019 were located in California, Florida, and New York, which sold $730 million, $291 million, and $215 million, respectively. Of the patients who use CBD, the most common reasons for their use were pain, anxiety, and insomnia. As the use of CBD for the relief of different issues increases, it is important to assess the safety and efficacy of CBD as it pertains to drug-drug interactions, lab interactions, and its actual benefits. This subject of safety and efficacy is increasingly important as the use of CBD has increased, with approximately 64 million Americans having tried CBD between 2017 and 2019. In this article, we will discuss these different aspects of CBD use from the point of view of a pharmacist. Not only do pharmacists commonly get questions on different aspects of CBD use, but they are also drug experts in areas including drug-drug interactions, drug toxicities, pharmacokinetics and pharmacodynamic profiles of medications, and guideline - recommended therapeutic options. Although there is a limited amount of data, there is still accessible data that may serve to inform pharmacists to become aware of the safety and efficacy of CBD. This information will serve pharmacists to educate patients that CBD contains properties to be used in a variety of conditions such as Lennox-Gastaut Syndrome, Dravet Syndrome, pain, and sports enhancement.
KeywordsCBDCannabidiolCannabinoid
Grinspoon, P. (2020) Cannabidiol (CBD)—What We Know and What We Don’t. Harvard Health. https://www.health.harvard.edu/blog/cannabidiol-cbd-what-we-know-and-what-we-dont-2018082414476
CANNABIDIOL (CBD) (2021) Pre-Review Report. World Health Organization, Geneva. https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf
Greenwich Biosciences. Epidiolex (CANNABIDIOL). U.S. Food and Drug Administration Website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
Machado, B.M., Helena, C.Q.R., Waldo, Z.A. and Crippa, A.S. (2011) Safety and Side Effects of Cannabidiol, a Cannabis sativa Constituent. Current Drug Safety, 6, 237-249. https://doi.org/10.2174/157488611798280924
Zanger, U.M. and Schwab, M. (2013) Cytochrome P450 Enzymes in Drug Metabolism: Regulation of Gene Expression, Enzyme Activities, and Impact of Genetic Variation. Pharmacology & Therapeutics, 138, 103-141. https://doi.org/10.1016/j.pharmthera.2012.12.007
Brown, J.D. and Winterstein, A.G. (2019) Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use. Journal of Clinical Medicine, 8, 989. https://doi.org/10.3390/jcm8070989
Pertwee, R.G. (2008) The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Δ9-Tetrahydrocannabinol, Cannabidiol and Δ9-Tetrahydrocannabivarin. British Journal of Pharmacology, 153, 199-215. https://doi.org/10.1038/sj.bjp.0707442
Arzimanoglou, A., Brandl, U., Cross, J.H., Gil-Nagel, A., Lagae, L., Landmark, C.J., Specchio, N., Nabbout, R., Thiele, E.A. and Gubbay, O. (2020) The Cannabinoids International Experts Panel; Collaborators. Epilepsy and Cannabidiol: A Guide to Treatment. Epileptic Disorders, 22, 1-14.
McCartney, D., Benson, M.J., Desbrow, B., Irwin, C., Suraev, A. and McGregor, I.S. (2020) Cannabidiol and Sports Performance: A Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Medicine—Open, 6, 27. https://doi.org/10.1186/s40798-020-00251-0
Booz, G.W. (2011) Cannabidiol as an Emergent Therapeutic Strategy for Lessening the Impact of Inflammation on Oxidative Stress. Free Radical Biology & Medicine, 51, 1054-1061. https://doi.org/10.1016/j.freeradbiomed.2011.01.007
Boyaji, S., Merkow, J., Elman, R.N.M., Kaye, A.D., Yong, R.J. and Urman, R.D. (2020) The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence. Current Pain and Headache Reports, 24, 4. https://doi.org/10.1007/s11916-020-0835-4
Lyden, J. and Binswanger, I.A. (2019) The United States Opioid Epidemic. Seminars in Perinatology, 43, 123-131. https://doi.org/10.1053/j.semperi.2019.01.001
Wade, D.T., Robson, P., House, H., Makela, P. and Aram, J. (2003) A Preliminary Controlled Study to Determine Whether Whole-Plant Cannabis Extracts Can Improve Intractable Neurogenic Symptoms. Clinical Rehabilitation, 17, 21-29. https://doi.org/10.1191/0269215503cr581oa
Gamelin, F.X., Cuvelier, G., Mendes, A., Aucouturier, J., Berthoin, S., Di Marzo, V. and Heyman, E. (2020) Cannabidiol in Sport: Ergogenic or Else? Pharmacological Research, 156, Article ID: 104764. https://doi.org/10.1016/j.phrs.2020.104764
Peake, J.M., Neubauer, O., Della Gatta, P.A. and Nosaka, K. (2017) Muscle Damage and Inflammation during Recovery from Exercise. Journal of Applied Physiology, 122, 559-570. https://doi.org/10.1152/japplphysiol.00971.2016
Costa, B., Giagnoni, G., Franke, C., Trovato, A.E. and Colleoni, M. (2004) Vanilloid TRPV1 Receptor Mediates the Antihyperalgesic Effect of the Nonpsychoactive Cannabinoid, Cannabidiol, in a Rat Model of Acute Inflammation. British Journal of Pharmacology, 143, 247-250. https://doi.org/10.1038/sj.bjp.0705920
Costa, B., Colleoni, M., Conti, S., Parolaro, D., Franke, C., Trovato, A.E. and Giagnoni, G. (2004) Oral Anti-Inflammatory Activity of Cannabidiol, a Non-Psycho-active Constituent of Cannabis, in Acute Carrageenan-Induced Inflammation in the Rat Paw. Naunyn-Schmiedeberg’s Archives of Pharmacology, 369, 294-299. https://doi.org/10.1007/s00210-004-0871-3
White, H.L. and Tansik, R.L. (1980) Effects of Delta 9-Tetrahydrocannabinol and Cannabidiol on Phospholipase and Other Enzymes Regulating Arachidonate Metabolism. Prostaglandins and Medicine, 4, 409-417. https://doi.org/10.1016/0161-4630(80)90049-X
Formukong, E.A., Evans, A.T. and Evans, F.J. (1988) Analgesic and Antiinflammatory Activity of Constituents of Cannabis sativa L. Inflammation, 12, 361-371. https://doi.org/10.1007/BF00915771
De Gregorio, D., McLaughlin, R.J., Posa, L., Ochoa-Sanchez, R., Enns, J., Lopez-Canul, M., Aboud, M., Maione, S., Comai, S. and Gobbi, G. (2019) Cannabidiol Modulates Serotonergic Transmission and Reverses both Allodynia and Anxiety-Like Behavior in a Model of Neuropathic Pain. Pain, 160, 136-150. https://doi.org/10.1097/j.pain.0000000000001386
Philpott, H.T., O’Brien, M. and McDougall, J.J. (2017) Attenuation of Early Phase Inflammation by Cannabidiol Prevents Pain and Nerve Damage in Rat Osteoarthritis. Pain, 158, 2442-2451. https://doi.org/10.1097/j.pain.0000000000001052
Malfait, A.M., Gallily, R., Sumariwalla, P.F., Malik, A.S., Andreakos, E., Mechoulam, R. and Feldmann, M. (2000) The Nonpsychoactive Cannabis Constituent Cannabidiol Is an Oral Anti-Arthritic Therapeutic in Murine Collagen-Induced Arthritis. Proceedings of the National Academy of Sciences of the United States of America, 97, 9561-9566. https://doi.org/10.1073/pnas.160105897
White, C.M. (2019) A Review of Human Studies Assessing Cannabidiol’s (CBD) Therapeutic Actions and Potential. The Journal of Clinical Pharmacology, 59, 923-934. https://doi.org/10.1002/jcph.1387
Reardon, C.L., Hainline, B., Aron, C.M., Baron, D., Baum, A.L., Bindra, A., Budgett, R., Campriani, N., Castaldelli-Maia, J.M., Currie, A., Derevensky, J.L., Glick, I.D., Gorczynski, P., Gouttebarge, V., Grandner, M.A., Han, D.H., McDuff, D., Mountjoy, M., Polat, A., Purcell, R., Putukian, M., Rice, S., Sills, A., Stull, T., Swartz, L., Zhu, L.J. and Engebretsen, L. (2019) Mental Health in Elite Athletes: International Olympic Committee Consensus Statement. British Journal of Sports Medicine, 53, 667-699. https://doi.org/10.1136/bjsports-2019-100715
Crippa, J.A., Zuardi, A.W., Garrido, G.E., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P.M., Hallak, J.E., McGuire, P.K. and Filho Busatto, G. (2004) Effects of Cannabidiol (CBD) on Regional Cerebral Blood Flow. Neuropsychopharmacology, 29, 417-426. https://doi.org/10.1038/sj.npp.1300340
Zuardi, A.W., Cosme, R.A., Graeff, F.G. and Guimarães, F.S. (1993) Effects of Ipsapirone and Cannabidiol on Human Experimental Anxiety. Journal of Psychopharmacology, 7, 82-88. https://doi.org/10.1177/026988119300700112
Papagianni, E.P. and Stevenson, C.W. (2019) Cannabinoid Regulation of Fear and Anxiety: An Update. Current Psychiatry Reports, 21, 38. https://doi.org/10.1007/s11920-019-1026-z
Single Care Team. Updated on Jan. 21, Team SC, Team SC. How Popular Is CBD? The Checkup.